Copilot
Your everyday AI companion
  1. CDC
    https://www.cdc.gov/vaccines/vpd/rsv/public/child.html

    RSV Vaccination: What Parents Should Know | CDC

    • Nirsevimab is a preventive antibody product for infants and young children who are at risk for severe RSV disease. Learn who should get nirsevimab, how it works, and what are the possible side effects.… See more

    Overview

    Nirsevimab (Beyfortus) is an immunization recommended for all infants younger than 8 … See more

    CDC
    When is RSV season?

    In most regions of the United States, RSV season starts in the fall and peaks in the winter, but the timing and severity of RSV season can vary from place to place and year to yea… See more

    CDC
    How can RSV disease be prevented?

    RSV disease can be prevented either by giving antibody products to infants and young children, or by giving their mothers RSV vaccine during pregnancy. For most babies, eith… See more

    CDC
    Who should get nirsevimab?

    •Nirsevimab is recommended for infants younger than 8 months of age who were born during or are entering their first RSV season if
    •The mothe… See more

    CDC
    Who should not get nirsevimab?

    Children 8 months old and older who are not at increased risk for severe RSV disease  should not receive nirsevimab.
    Except in rare circumstances, most infants younger th… See more

    CDC
    How well does nirsevimab work?

    Nirsevimab reduces the risk of severe RSV disease by about 80%. One dose of nirsevimab protects infants for at least 5 months, the length of an average RSV season. Be… See more

    CDC
    Feedback
  1. CDC
    https://www.cdc.gov/vaccines/vpd/rsv/downloads/immuni…PDF file

    Respiratory Syncytial Virus (RSV)

  2. People also ask
    Who should take nirsevimab (beyfortus)?
    Nirsevimab (Beyfortus) is a monoclonal antibody product that can protect infants and some young children from severe RSV disease. It is recommended for: Some children between the ages of 8 and 19 months who are at increased risk of severe RSV disease before their second RSV season. These include:

    For Healthcare Professionals: RSV (Respiratory Syncytial Virus) | CDC

    cdc.gov
    What is beyfortus?
    Beyfortus is the only monoclonal antibody approved for passive immunisation to provide safe and effective protection for all infants during their first RSV season. I am proud that, by prioritising this potential game-changer, we are now about to bring Beyfortus to American families.”

    Beyfortus approved in the US for the prevention of RSV lower

    astrazeneca.com
    What is nirsevimab (beyfortus)?
    Nirsevimab (Beyfortus) is an immunization recommended for all infants younger than 8 months of age who are born during—or who are entering—their first Respiratory Syncytial Virus (RSV) season.

    RSV Vaccination: What Parents Should Know | CDC

    cdc.gov
    Is beyfortus a preventive option?
    Beyfortus is the first preventive option approved to protect a broad infant population, including those born healthy at term, or preterm, or with specific health conditions that make them vulnerable to severe RSV disease.

    Beyfortus approved in the US for the prevention of RSV lower

    astrazeneca.com
    Feedback
  3. Emergency Preparedness and Response | CDC
    https://emergency.cdc.gov/han/2023/han00499.asp

    Health Alert Network (HAN) - 00499 | Limited Availability of ... - CDC

  4. AstraZeneca
    https://www.astrazeneca.com/media-centre/press-releases/2023/bey…

    Beyfortus approved in the US for the prevention of RSV lower ...

  6. Food and Drug Administration (.gov)
    https://www.fda.gov/news-events/press-announcements/fda-approve…

    FDA Approves New Drug to Prevent RSV in Babies and Toddlers